[go: up one dir, main page]

WO2008030390A2 - Compositions ophtalmiques pour le traitement de l'hypertension oculaire - Google Patents

Compositions ophtalmiques pour le traitement de l'hypertension oculaire Download PDF

Info

Publication number
WO2008030390A2
WO2008030390A2 PCT/US2007/019123 US2007019123W WO2008030390A2 WO 2008030390 A2 WO2008030390 A2 WO 2008030390A2 US 2007019123 W US2007019123 W US 2007019123W WO 2008030390 A2 WO2008030390 A2 WO 2008030390A2
Authority
WO
WIPO (PCT)
Prior art keywords
methoxy
indazol
isobutyryl
alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019123
Other languages
English (en)
Other versions
WO2008030390A3 (fr
Inventor
James B. Doherty
Min Shu
Dong-Ming Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2008030390A2 publication Critical patent/WO2008030390A2/fr
Publication of WO2008030390A3 publication Critical patent/WO2008030390A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Definitions

  • Glaucoma is a degenerative disease of the eye wherein the intraocular pressure is too high to permit normal eye function. As a result, damage may occur to the optic nerve head and result in irreversible loss of visual function. If untreated, glaucoma may eventually lead to blindness. Ocular hypertension, i.e., the condition of elevated intraocular pressure without optic nerve head damage or characteristic glaucomatous visual field defects, is now believed by the majority of ophthalmologists to represent merely the earliest phase in the onset of glaucoma.
  • This invention relates to the compounds of formula I and their use as potent potassium channel blockers or formulations thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient.
  • This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. More particularly this invention relates to the treatment of glaucoma and/or ocular hypertension (elevated intraocular pressure) using novel bidentate compounds having the structural formula I:
  • Yl and Y2 independently represent O or H2;
  • Y represents -CO(CH2) n R5-, -(CH2) n R5, or -CH(OR)Rs;
  • Q and Q' are O, NR, or a bond
  • W is a Ci-IO alkyl di-radical optionally interrupted by zero to three groups of C ⁇ -io aryl, C5-IO heteroaryl, C3.10 cycloalkyl, C5-10 heterocycle, zero to four groups of O, S, SO, SO2, or NR, or a combination thereof and optionally substituted with one to three groups of R a ;
  • W can be from one to three di-radical groups selected from the group consisting of C 6 -IO aryl, C5-10 heteroaryl, C3-10 cycloalkyl, C5-10 heterocycle, wherein when there is more than one di- radical present, said di -radicals are connected with each other using zero to two C 1.5 alkyl di- radical, zero to four groups of O, S, SO, SO2, or NR, or a combination thereof and optionally substituted with one to three groups of Ra ;
  • X and X' represent -(CHR7) p -;
  • Z, Zi, Z2, Z3, Z4, Z5, Z6, and Z7 are independently selected from CH or N;
  • R represents hydrogen, C 1-6 alkyl, -(CH2)nC3-8 cycloalkyl, -(CH2)nC3-l ⁇ heterocyclyl, - (CH2)nC6-10 aryl, said alkyl, cycloalkyl and aryl optionally substituted with one to three groups of Ra;
  • R2 and R3 independently represent hydrogen, Ci_io alkyl, OH, -(CH2)nC3-8 cycloalkyl, -
  • Rl and R4 independently represent hydrogen, Ci-6 alkoxy, OH, Ci-6 alkyl, COOR, SOqCi-6 alkyl, COC 1-6 alkyl, SO3H, -O(CH 2 ) n N(R) 2 , -O(CH 2 ) n CO 2 R, -OPO(OH) 2 , CF3, OCF3 - N(R) 2 , nitro, cyano, Cl -6 alkylamino, or halogen; and
  • R5 represents hydrogen, Ci-io alkyl, -(CH 2 ) n C6-10 aryl, NR 0 Rd, -NR(CH 2 ) n C6-10 aryl, - N((CH 2 ) n C6-10 aryl) 2 , -(CH 2 ) n C3_io heterocyclyl, -NR(CH 2 ) n C3-io heterocyclyl, - N((CH 2 ) n C 3 -10 heterocyclyl) 2 , (C 6 -IO aryl)O-, -(CH 2 ) n OPO(OR) 2 , -(CH 2 ) n C 3 -8 cycloalkyl, - COOR, -C(O)CO 2 R, said aryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from Ra, wherein the Ra(s) can be attached to any carbon atom or heteroatom selected from N and S;
  • R c and Rd independently represent H, C 1-6 alkyl, C 2 -6 alkenyl, Cl -6 alkylSR, - (CH 2 ) n O(CH 2 ) m OR, -(CH 2 ) n Ci- 6 alkoxy, or -(CH 2 ) n C3_8 cycloalkyl; or Rc and Rd taken together with the intervening N atom form a 4-10 membered heterocyclic - carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R a ;
  • R7 represents hydrogen, C l -6 alkyl, -(CH2) n COOR or -(CH2) n N(R)2,
  • R8 represents -(CH2) n C3-8 cycloalkyl, -(CH2)nC3-lO heterocyclyl, Cl -6 alkoxy or -(CH2)nC5- 10 heteroaryl, -(CH2)nC6-10 aryl said heterocyclyl, aryl or heteroaryl optionally substituted with 1 -3 groups selected from Ra;
  • Ra represents F, Cl, Br, I, CF 3 , N(R) 2 , NO 2 , CN, -O-, -CORg, -CONHRg, -CON(Rg)2, - O(CH2) n COOR, -NH(CH 2 ) n OR, -COOR, -OCF3, CF 2 CH 2 OR, -NHCOR, -SO2R, -SO2NR2, - SR, (C 1 -C 6 alkyl)O-, -(CH 2 )n0(CH 2 )m0R, -(CH 2 ) n Cl-6 alkoxy, (aryl)O-, -(CH 2 ) n OH, (C 1 - C 6 alkyl)S(O) m -, H 2 N-C(NH)-, (C 1 -C 6 alkyl)C(O)-, (C 1 -C 6 alkyl)OC(O)NH-, -(C 1
  • R w represents H, Cl -6 alkyl, -C(O)C i_ 6 alkyl, -C(O)OCi -6 alkyl, -S ⁇ 2N(R)2, -S ⁇ 2Ci_ 6 alkyl, - SO2C6-IO aryl, NO 2 , CN or -C(O)N(R) 2 ;
  • the present invention is directed to novel potassium channel blockers of Formula I. It also relates to a method for decreasing elevated intraocular pressure or treating glaucoma by administration, preferably topical or intra-camaral administration, of a composition containing a potassium channel blocker of Formula I described hereinabove and a pharmaceutically acceptable carrier.
  • Another embodiment of this invention is realized when Y is -(CH2)nR5 and all other variables are as originally described. A subembodiment of this invention is realized when n is O. Another embodiment of this invention is realized when Y is -CO(CH2)nR5 and all other variables are as originally described. A subembodiment of this invention is realized when n is 0.
  • Another embodiment of this invention is realized when Y is CH(OR)Rs and all other variables are as originally described.
  • X and X' independently are -(CHR7)p-, p is 1-3 and all other variables are as originally described.
  • Still another embodiment of this invention is realized when Z is N and all other variables are as originally described.
  • Still another embodiment of this invention is realized when Z is CH and all other variables are as originally described.
  • Another embodiment of this invention is realized when Zi, Z2, Z3, Z4, Z5, Z ⁇ , and Z7 are CH and all other variables are as originally described.
  • Yet another embodiment of this invention is realized when one of Q and Q' is NR and the other is O and all other variables are as originally described.
  • Another embodiment of this invention is realized when both Q and Q' are NR and all other variables are as originally described.
  • W is a 2-10 alkyl di- radical interrupted by C6-10 ary ⁇ C5-IO heterocyclyl, C3-IO cycloalkyl, or C5.10 heteraryl and optionally substituted with one to three groups of R a ,and all other variables are as originally described.
  • W can be from one to three di-radical groups selected from the group consisting of C6-10 aryl C5-10 heteroaryl, C3-10 cycloalkyl, C5-IO heterocycle, wherein when there is more than one di-radical present, said di- radicals are connected with each other using zero to two C] .5 alkyl di-radical, zero to four groups of O, S, SO, SO2, or NR, or a combination thereof and optionally substituted with one to three groups ofR a and all other variables are as originally described.
  • R is H or Cl -6 alkyl and all other variables are as originally described.
  • R4 is C 1-6 alkoxy and all other variables are as originally described.
  • a sub-embodiment of this invention is realized when Zi, Z2, and Z3 are CH, Y is -C(O)(CH2)nR5 and Q and Q' are independently O or NR. Another sub-embodiment of this invention is realized when R4 is Cl -6 alkoxy. Another sub-embodiment of this invention is realized when both Q and Q' are NR. Still another sub-embodiment of this invention is realized when one of Q and Q' is NR and the other is O.
  • a sub-embodiment of this invention is realized when Zi, Z2, and Z3 are CH, Y is -(CH2)nR-5 and Q and Q' are independently O or NR. Another sub-embodiment of this invention is realized when R4 is Ci_6 alkoxy. Another sub-embodiment of this invention is realized when both Q and Q' are NR. Still another sub-embodiment of this invention is realized when one of Q and Q' is NR and the other is O. Another embodiment of this invention is realized when V and V both are
  • Preferred compounds used in this invention are:
  • the invention is described herein in detail using the terms defined below unless otherwise specified.
  • the compounds of the present invention may have asymmetric centers, chiral axes and chiral planes, and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. (See E.L. Eliel and S. H. Wilen Stereochemistry of Carbon Compounds (John Wiley and Sons, New York 1994), in particular pages 1119-1190)
  • any variable e.g. aryl, heterocycle, R.1, R ⁇ etc.
  • its definition on each occurrence is independent at every other occurrence.
  • combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
  • R a When R a is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
  • a nitrogen e.g., nitrogen atom on a pyridyl group
  • sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
  • alkyl refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 10 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, cyclopropyl cyclopentyl and cyclohexyl. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group”.
  • Cycloalkyl is a specie of alkyl containing from 3 to 15 carbon atoms, unless otherwise defined, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings, which are fused. Examples of such cycloalkyl elements include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Alkenyl is C2-C6 alkenyl.
  • Alkoxy refers to an alkyl group of indicated number of carbon atoms attached through an oxygen bridge, with the alkyl group optionally substituted as described herein. Said groups are those groups of the designated length in either a straight or branched configuration and if two or more carbon atoms in length, they may include a double or a triple bond. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy allyloxy, propargyloxy, and the like.
  • Halogen refers to chlorine, fluorine, iodine or bromine.
  • Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and the like, as well as rings which are fused, e.g., naphthyl, phenanthrenyl and the like.
  • An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms.
  • aryl groups are phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl and phenanthrenyl, preferably phenyl, naphthyl or phenanthrenyl.
  • Aryl groups may likewise be . - substituted as defined.
  • Preferred substituted aryls include phenyl and naphthyl.
  • heterocyclyl or heterocyclic represents a stable 3- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated ⁇ and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • a fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.
  • heterocycle or heterocyclic includes heteroaryl moieties.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, dihydropyrrolyl, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholin
  • heterocycle is selected from 2-azepinonyl, benzimidazolyl, 2-diazapinonyl, dihydroimidazolyl, dihydropyrrolyl, imidazolyl, 2-imidazolidinonyl, indolyl, isoquinolinyl, morpholinyl, piperidyl, piperazinyl, pyridyl, pyrrolidinyl, 2-piperidinonyl, 2-pyrimidinonyl, 2-pyrollidinonyl, quinolinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, and thienyl.
  • heteroatom means O, S or N, selected on an independent basis.
  • heteroaryl refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein.
  • heterocyclic elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinazolin
  • compositions and methods of treating ocular hypertension or glaucoma by administering to a patient in need thereof one of the compounds of formula I in combination with a ⁇ -adrenergic blocking agent such as timolol, betaxolol, levobetaxolol, carteolol, levobunolol, a parasympathomimetic agent such as epinephrine, iopidine, brimonidine, clonidine, para-aminoclonidine, carbonic anhydrase inhibitor such as dorzolamide, acetazolamide, metazolamide or brinzolamide, an EP4 agonist (such as those disclosed in WO 02/24647, WO 02/42268, EP 1114816, WO 01/46140 and WO 01/72268), a prostaglandin such as la
  • a ⁇ -adrenergic blocking agent such as timolol, betaxolol, levobetaxolo
  • hypotensive lipid (the carboxylic acid group on the ⁇ -chain link of the basic prostaglandin structure is replaced with electrochemically neutral substituents) is that in which the carboxylic acid group is replaced with a C 1-6 alkoxy group such as OCH3 (PGF2 a I-OCH3), or a hydroxy group (PGF2a 1-OH).
  • Preferred potassium channel blockers are calcium activated potassium channel blockers. More preferred potassium channel blockers are high conductance, calcium activated potassium (Maxi-K) channel blockers. Maxi-K channels are a family of ion channels that are prevalent in neuronal, smooth muscle and epithelial tissues and which are . gated by membrane potential and intracellular Ca2+.
  • the present invention is based upon the finding that maxi-K channels, if blocked, inhibit aqueous humor production by inhibiting net solute and H2O efflux and therefore lower IOP.
  • maxi-K channel blockers are useful for treating other ophthamological dysfunctions such as macular edema and macular degeneration. It is known that lowering IOP promotes blood flow to the retina and optic nerve. Accordingly, the compounds of this invention are useful for treating macular edema and/or macular degeneration. It is believed that maxi-K channel blockers which lower IOP are useful for providing a neuroprotective effect.
  • this invention further relates to a method for increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension as well as providing a neuroprotective effect or a combination thereof.
  • a number of marketed drugs function as potassium channel antagonists. The most important of these include the compounds Glyburide, Glipizide and Tolbutamide. These potassium channel antagonists are useful as antidiabetic agents.
  • the compounds of this invention may be combined with one or more of these compounds to treat diabetes. Potassium channel antagonists are also utilized as Class 3 antiarrhythmic agents and to treat acute infarctions in humans.
  • a number of naturally occuring toxins are known to block potassium channels including Apamin, Iberiotoxin, Charybdotoxin, Noxiustoxin, Kaliotoxin, Dendrotoxin(s), mast cell degranuating (MCD) peptide, and ⁇ -Bungarotoxin ( ⁇ - BTX).
  • the compounds of this invention may be combined with one or more of these compounds to treat arrhythmias.
  • Depression is related to a decrease in neurotransmitter release.
  • Current treatments of depression include blockers of neurotransmitter uptake, and inhibitors of enzymes involved in neurotransmitter degradation which act to prolong the lifetime of neurotransmitters.
  • Alzheimer's disease is also characterized by a diminished neurotransmitter release.
  • Three classes of drugs are being investigated for the treatment of Alzheimer's disease cholinergic potentiators such as the anticholinesterase drugs (e.g., physostigmine (eserine), and Tacrine (tetrahydroaminocridine)); nootropics that affect neuron metabolism with little effect elsewhere (e.g., Piracetam, Oxiracetam; and those drugs that affect brain vasculature such as a mixture of ergoloid mesylates amd calcium channel blocking drugs including Nimodipine.
  • anticholinesterase drugs e.g., physostigmine (eserine), and Tacrine (tetrahydroaminocridine)
  • nootropics that affect neuron metabolism with little effect elsewhere
  • Piracetam, Oxiracetam e.g., Piracetam, Oxiracetam
  • those drugs that affect brain vasculature such
  • Selegiline a monoamine oxidase B inhibitor which increases brain dopamine and norepinephrine has reportedly caused mild improvement in some Alzheimer's patients.
  • Aluminum chelating agents have been of interest to those who believe Alzheimer's disease is due to aluminum toxicity.
  • Drugs that affect behavior, including neuroleptics, and anxiolytics have been employed.
  • Anxiolytics, which are mild tranquilizers, are less effective than neuroleptics
  • the present invention is related to novel compounds which are useful as potassium channel antagonists. The compounds within the scope of the present invention exhibit potassium channel antagonist activity and thus are useful in disorders associated with potassium channel malfunction.
  • a number of cognitive disorders such as Alzheimer's Disease, memory loss or depression may benefit from enhanced release of neurotransmitters such as serotonin, dopamine or acetylcholine and the like.
  • Blockage of Maxi-K channels maintains cellular depolarization and therefore enhances secretion of these vital neurotransmitters.
  • the compounds of this invention may be combined with anticholinesterase drugs such as physostigmine (eserine) and Tacrine (tetrahydroaminocridine), nootropics such as Piracetam, Oxiracetam, ergoloid mesylates, selective calcium channel blockers such as Nimodipine, or monoamine oxidase B inhibitors such as Selegiline, in the treatment of
  • anticholinesterase drugs such as physostigmine (eserine) and Tacrine (tetrahydroaminocridine)
  • nootropics such as Piracetam, Oxiracetam, ergoloid mesylates
  • selective calcium channel blockers such as Nimodipine
  • monoamine oxidase B inhibitors such as Selegiline
  • the compounds of this invention may also be combined with Apamin, Iberiotoxin, Charybdotoxin, Noxiustoxin, Kaliotoxin, Dendrotoxin(s), mast cell degranuating (MCD) peptide, ⁇ -Bungarotoxin ( ⁇ -BTX) or a combination thereof in treating arrythmias.
  • the compounds of this invention may further be combined with Glyburide, Glipizide, Tolbutamide or a combination thereof to treat diabetes.
  • each of the claimed compounds are potassium channel antagonists and are thus useful in the decribed neurological disorders in which it is desirable to maintain the cell in a depolarized state to achieve maximal neurotransmitter release.
  • the compounds produced in the present invention are readily combined with suitable and known pharmaceutically acceptable excipients to produce compositions which may be administered to mammals, including humans, to achieve effective potassium channel blockage.
  • salts of the compounds of formula I will be pharmaceutically acceptable salts.
  • Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
  • suitable “pharmaceutically acceptable salts” refers to salts prepared form pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, N,N'-dibenzylethylenediamine, diethylamin, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.
  • basic ion exchange resins such as arginine, betaine
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, carnphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
  • composition is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.
  • the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, sex and response of the individual patient, as well as the severity of the patient's symptoms.
  • the maxi-K channel blockers used can be administered in a therapeutically effective amount intravaneously, subcutaneously, topically, transdermally, parenterally or any other method known to those skilled in the art.
  • Ophthalmic pharmaceutical compositions are preferably adapted for topical administration to the eye in the form of solutions, suspensions, ointments, creams or as a solid insert.
  • Ophthalmic formulations of this compound may contain from 0.01 ppm to 1% and especially 0.1 ppm to 1% of medicament. Higher dosages as, for example, about 10% or lower dosages can be employed provided the dose is effective in reducing intraocular pressure, treating glaucoma, increasing blood flow velocity or oxygen tension.
  • For a single dose from between 0.01 to 5000 ng, preferably 0.1 to 500 ng, and especially 1 to 100 ng of the compound can be - applied to the human eye.
  • the pharmaceutical preparation which contains the compound may be conveniently admixed with a non-toxic pharmaceutical organic carrier, or with a non-toxic pharmaceutical inorganic carrier.
  • a non-toxic pharmaceutical organic carrier or with a non-toxic pharmaceutical inorganic carrier.
  • pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethyl-cellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally employed acceptable carriers.
  • the pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non- injurious in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredients such as sodium borate, sodium acetates, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, polyoxyethylene sorbitan monopalmitylate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetracetic acid, and the like.
  • auxiliary substances such as e
  • suitable ophthalmic vehicles can be used as carrier media for the present purpose including conventional phosphate buffer vehicle systems, isotonic boric acid vehicles, isotonic sodium chloride vehicles, isotonic sodium borate vehicles and the like.
  • the pharmaceutical preparation may also be in the form of a microparticle formulation.
  • the pharmaceutical preparation may also be in the form of a solid insert. For example, one may use a solid water soluble polymer as the carrier for the medicament.
  • the polymer used to form the insert may be any water soluble non-toxic polymer, for example, cellulose derivatives such as methylcellulose, sodium carboxymethyl cellulose, (hydroxyloweralkyl cellulose), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose; acrylates such as polyacrylic acid salts, ethylacrylates, polyactylamides; natural products such as gelatin, alginates, pectins, tragacanth, karaya, chondrus, agar, acacia; the starch derivatives such as starch acetate, hydroxymethyl starch ethers, hydroxypropyl starch, as well as other synthetic derivatives such as polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, polyethylene oxide, neutralized carbopol and xanthan gum, gellan gum, and mixtures of said polymer.
  • cellulose derivatives such as methylcellulose, sodium carboxymethyl
  • Suitable subjects for the administration of the formulation of the present invention include primates, man and other animals, particularly man and domesticated animals such as cats and dogs.
  • the pharmaceutical preparation may contain non-toxic auxiliary substances such as antibacterial components which are non-injurious in use, for example, thimerosal, benzalkonium chloride, methyl and propyl paraben, benzyldodecinium bromide, benzyl alcohol, or phenylethanol; buffering ingredients such as sodium chloride, sodium borate, sodium acetate, sodium citrate, or gluconate buffers; and other conventional ingredients such as sorbitan monolaurate, triethanolamine, polyoxyethylene sorbitan monopalmitylate, ethylenediamine tetraacetic acid, and the like.
  • the ophthalmic solution or suspension may be administered as often as necessary to maintain an acceptable IOP level in the eye. It is contemplated that administration to the malian eye will be about once or twice daily.
  • novel formulations of this invention may take the form of solutions, gels, ointments, suspensions or solid inserts, formulated so that a unit dosage comprises a therapeutically effective amount of the active component or some multiple thereof in the case of a combination therapy.
  • a unit dosage comprises a therapeutically effective amount of the active component or some multiple thereof in the case of a combination therapy.
  • the compounds of this invention can be made, with modification where appropriate, in accordance with Scheme 1.
  • the compounds of this invention are illustrated with bis amide or amide ester class of compounds. Many methods are known for the preparation of these general classes of compounds. One method is to couple acid with a diamine or a hydroxylamine. Another would be using a carboxylic acid derivative such as acyl halide as the starting material instead of the acid itself.
  • the examples below used the direct coupling of acid and a diamine or a hydroxylamine by way of illustration as shown in Scheme 1.
  • Step B N,iV-Diethylhexane- 1 ,6-diamine
  • reaction mixture After refiuxing for 30 minutes following completion of the addition of the amide, the reaction mixture was cooled to room temperature and 7.98 g more LAH was added. The resulting mixture was heated in the oil bath for six days. After cooling to room temperature, the reaction mixture was quenched by addition of 0.2 mL portions of saturated aqueous Na 2 SO 4 solution till no more gas was formed. Then the whole reaction mixture was evaporated to dryness under reduced pressure. The solid residue was transferred to a funnel and washed with 2x350 mL ether. The ether filtrate was concentrated under reduced pressure, filtered through a syringe filter to remove a small amount of precipitate, and evaporated to give the title compound as 5.28 g colorless liquid.
  • Step B N,N-Bis(3,3-dimethylbutyl)ethane-l,2-diamine
  • Step B 2,2'-Piperazine-l,4-diylbis(N-ethylethanamine)
  • the title compound was prepared from N,N'-(piperazine-l,4-diyldiethane-2,l-diyl)diacetamide from Step A above using method in Step B
  • Preparative Example 4 1 H NMR (CDCl 3 , 500 MHz) ⁇ 2.74 (t, 6.3 Hz, 4H), 2.69 (q, 7.1 Hz, 4H), 2.52 (t, 6.3 Hz, 4H), 2.45-2.52 (m, 8H), 1.14 (t, 7.1 Hz, 6H).
  • Step B ⁇ yV-bis(3, 3 -dimethylbutyl)pentane- 1,5 -diamine
  • the Compound A was prepared from 6 mg ((3-ter/-Butyl-7-methoxy-2-oxoquinoxalin- l(2H)-yl)acetic acid, 6 ⁇ L di-n-butylamine, 8 mg EDC, 6 mg HOBt, and 15 ⁇ L DIEA in 1 mL DMF at room temperature and purified using preparative HPLC followed by lyophilization.
  • the Compound B was prepared from 6 mg ((3-tert-Butyl-7-methoxy-2- oxoquinoxalin-l(2H)-yl)acetic acid, 6 ⁇ L di-n-butylamine, 8 mg EDC, 6 mg HOBt, and 15 ⁇ L DIEA in 1 mL DMF at room temperature and purified using preparative HPLC followed by lyophilization.
  • Examples 3-7 in Table 1 were prepared from [2-(2,2-dimethylpropanoyl)-6-methoxy-lH- benzimidazol-1-yl] acetic acid and appropriate hydroxylamine (HNR(ROH)) using methods similar to that used in Example 1 or 2.
  • Examples 8—19 in Table 2 were prepared from (3-isobutyryl-6-methoxy-lH- indazol-l-yl)acetic acid and appropriate hydroxylamine ( ⁇ NR(R'O ⁇ )) using methods similar to that used in Example 1 or 2.
  • Examples 24-33 in Table 3 were obtained from (3-ter/-butyl-7-methoxy-2- oxoquinoxalin-l(2H)-yl)acetic acid and appropriate amine (HNR'-R'-NR ⁇ ) using method described in Example 22. Instead of conducting the reaction at room temperature, these reactions were carried out at 45°C for 2 to 6 hours.
  • Examples 34-53 in Table 4 were obtained from (3-isobutyryl-6-methoxy-lH-indazol-l- yl)acetic acid and appropriate amine (HNR'-R'-NR' ⁇ ) using method described in Example 22. Some reactions were conducted at 40°C for a few hours.
  • Examples 54-53 in Table 5 were obtained from [3-(2,2-dimethylpropanoyl)-6-methoxy- l//-indazol-l-yl] acetic acid and appropriate amine (HNR'-R'-NR' ⁇ ) using method described in Example 22. Some reactions were conducted at 40°C for a few hours.
  • Examples 59-61 in Table 6 were prepared from [3-(2,2-dimethylpropanoyl)-6-methoxy- lH-indazol-1-yl] acetic acid and appropriate hydroxylamine (HR 5 N(ROH)) using methods similar to that used in Example 1 or 2.
  • the activity of the compounds can also be quantified by the following assay.
  • the identification of inhibitors of the Maxi-K channel is based on the ability of expressed Maxi-K channels to set cellular resting potential after transfection of both alpha and betal subunits of the channel in HEK-293 cells and after being incubated with potassium channel blockers that selectively eliminate the endogenous potassium conductances of HEK-293 cells. Ln the absence of maxi-K channel inhibitors, the transfected HEK-293 cells display a hyperpolarized membrane potential, negative inside, close to E K (-80 mV) which is a consequence of the activity of the maxi-K channel. Blockade of the Maxi-K channel by incubation with maxi-K channel blockers will cause cell depolarization. Changes in membrane potential can be determined with voltage-sensitive fluorescence resonance energy transfer (FRET) dye pairs that use two components, a donor coumarin (CC 2 DMPE) and an acceptor oxanol (DiSBAC 2 (3)).
  • FRET voltage-sensitive fluorescence resonance energy transfer
  • Oxanol is a lipophilic anion and distributes across the membrane according to membrane potential. Under normal conditions, when the inside of the cell is negative with respect to the outside, oxanol is accumulated at the outer leaflet of the membrane and excitation of coumarin will cause FRET to occur. Conditions that lead to membrane depolarization will cause the oxanol to redistribute to the inside of the cell, and, as a consequence, to a decrease in FRET. Thus, the ratio change (donor/acceptor) increases after membrane depolarization, which determines if a test compound actively blocks the maxi-K channel.
  • the HEK-293 cells were obtained from the American Type Culture Collection , 12301 Parklawn Drive, Rockville, Maryland, 20852 under accession number ATCC CRL-1573. Any restrictions relating to public access to the microorganism shall be irrevocably removed upon patent issuance.
  • HEK-293 cells were plated in 100 mm tissue culture treated dishes at a density of 3x10 6 cells per dish, and a total of five dishes were prepared. Cells were grown in a medium consisting of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine serum, IX L-Glutamine, and IX Penicillin/Streptomycin, at 37 0 C, 10% CO 2 .
  • DMEM Dulbecco's Modified Eagle Medium
  • cells were put under selection media which consisted of DMEM supplemented with both 600 ⁇ g/ml G418 and 0.75 ⁇ g/ml puromycin. Cells were grown until separate colonies were formed. Five colonies were collected and transferred to a 6 well tissue culture treated dish. A total of 75 colonies were collected. Cells were allowed to grow until a confluent monolayer was obtained. Cells were then tested for the presence of maxi-K channel alpha and betal subunits using an assay that monitors binding of 125 I-iberiotoxin-D19Y/Y36F to the channel.
  • Cells expressing 125 I-iberiotoxin-D19Y/Y36F binding activity were then evaluated in a functional assay that monitors the capability of maxi-K channels to control the membrane potential of transfected HEK-293 cells using fluorescence resonance energy transfer (FRET) ABS technology with a VIPR instrument.
  • FRET fluorescence resonance energy transfer
  • the colony giving the largest signal to noise ratio was subjected to limiting dilution. For this, cells were resuspended at approximately 5 cells/ml, and 200 ⁇ l were plated in individual wells in a 96 well tissue culture treated plate, to add ca. one cell per well. A total of two 96 well plates were made. When a confluent monolayer was formed, the cells were transferred to 6 well tissue culture treated plates.
  • the transfected cells (2E+06 Cells/mL) are then plated on 96-well poly-D-lysine plates at a density of about 100,000 cells/well and incubated for about 16 to about 24 hours. The medium is aspirated of the cells and the cells washed one time with 100 ⁇ l of Dulbecco's phosphate buffered saline (D-PBS).
  • D-PBS Dulbecco's phosphate buffered saline
  • One hundred microliters of about 9 ⁇ M coumarin (CC 2 DMPE)-0.02% pluronic-127 in D-PBS per well is added and the wells are incubated in the dark for about 30 minutes.
  • the cells are washed two times with 100 ⁇ l of Dulbecco's phosphate-buffered saline and 100 ⁇ l of about 4.5 ⁇ M of oxanol (DiSB AC 2 (3)) in (rnM) 140 NaCl, 0.1 KCl, 2 CaCl 2 , 1 MgCl 2 , 20 Hepes-NaOH, pH 7.4, 10 glucose is added.
  • Three micromolar of an inhibitor of endogenous potassium conductance of HEK-293 cells is added.
  • a maxi-K channel blocker is added (about 0.01 micromolar to about 10 micromolar) and the cells are incubated at room temperature in the dark for about 30 minutes.
  • the plates are loaded into a voltage/ion probe reader (VIPR) instrument, and the fluorescence emission of both CC 2 DMPE and DiSBAC 2 (3) are recorded for 10 sec.
  • VPR voltage/ion probe reader
  • 100 ⁇ l of high-potassium solution (mM): 140 KCl, 2 CaCl 2 , 1 MgCl 2 , 20 Hepes-KOH, pH 7.4, 10 glucose are added and the fluorescence emission of both dyes recorded for an additional 10 sec.
  • the ratio CC 2 DMPE/DiSBAC 2 (3), before addition of high-potassium solution equals 1.
  • the ratio after addition of high-potassium solution varies between 1.65-2.0.
  • the Maxi-K channel has been completely inhibited by either a known standard or test compound, this ratio remains at 1. It is possible, therefore, to titrate the activity of a Maxi-K channel inhibitor by monitoring the concentration-dependent change in the fluorescence ratio.
  • the compounds of this invention were found to cause concentration-dependent inhibition of the fluorescence ratio with ICso's in the range of about 10 nM to about 500 ⁇ M, more preferably from about 10 nM to about 50 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de puissants composés inhibiteurs des canaux potassiques de formule (I) ou une formulation de ceux-ci, destinés au traitement du glaucome et d'autres affections qui conduisent à une élévation de la pression intraoculaire dans l'œil d'un patient. L'invention concerne également l'utilisation de tels composés pour obtenir un effet neuroprotecteur de l'œil d'espèces de mammifères, en particulier d'humains.
PCT/US2007/019123 2006-09-05 2007-08-31 Compositions ophtalmiques pour le traitement de l'hypertension oculaire Ceased WO2008030390A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84222406P 2006-09-05 2006-09-05
US60/842,224 2006-09-05

Publications (2)

Publication Number Publication Date
WO2008030390A2 true WO2008030390A2 (fr) 2008-03-13
WO2008030390A3 WO2008030390A3 (fr) 2008-11-20

Family

ID=39157767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019123 Ceased WO2008030390A2 (fr) 2006-09-05 2007-08-31 Compositions ophtalmiques pour le traitement de l'hypertension oculaire

Country Status (1)

Country Link
WO (1) WO2008030390A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693059A (zh) * 2013-12-09 2015-06-10 中国科学院兰州化学物理研究所 二乙酰己二胺诱导分化剂的晶型及其制备方法和应用
CN113501796A (zh) * 2021-07-15 2021-10-15 大连理工大学 一种胺乙基化哌嗪及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563816B2 (en) * 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693059A (zh) * 2013-12-09 2015-06-10 中国科学院兰州化学物理研究所 二乙酰己二胺诱导分化剂的晶型及其制备方法和应用
CN113501796A (zh) * 2021-07-15 2021-10-15 大连理工大学 一种胺乙基化哌嗪及其制备方法

Also Published As

Publication number Publication date
WO2008030390A3 (fr) 2008-11-20

Similar Documents

Publication Publication Date Title
US20090062280A1 (en) Ophthalmic Compositions for Treating Ocular Hypertension
US20060148805A1 (en) Opthalmic compositions for treating ocular hypertension
AU2003287506B8 (en) Ophthalmic compositions for treating ocular hypertension
US7528163B2 (en) Ophthalmic compositions for treating ocular hypertension
US20070293558A1 (en) Ophthalmic Compositions for Treating Ocular Hypertension
US20090281154A1 (en) Ophthalmic Compositions for Treating Ocular Hypertension
WO2008030390A2 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
US7563816B2 (en) Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en) Ophthalmic compositions for treating ocular hypertension
AU2005295997A1 (en) Ophthalmic compositions for treating ocular hypertension
US20060154897A1 (en) Ophthalmic compositions for treating ocular hypertension
CA2519899A1 (fr) Compositions ophtalmiques pour traiter une hypertension oculaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837575

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07837575

Country of ref document: EP

Kind code of ref document: A2